Medicure Drug Patent Portfolio

Medicure owns 2 orange book drugs protected by 7 US patents Given below is the list of Medicure's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8829186 Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof 19 Jan, 2031
Active
US6770660 Method for inhibiting platelet aggregation 01 May, 2023 Expired
US6136794 Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist 29 Jan, 2019 Expired
US5978698 Angioplasty procedure using nonionic contrast media 08 Oct, 2017 Expired
US5733919 Compositions for inhibiting platelet aggregation 23 Oct, 2016 Expired
US5965581 Compositions for inhibiting platelet aggregation 23 Oct, 2016 Expired
US5972967 Compositions for inhibiting platelet aggregation 23 Oct, 2016 Expired


Given below is the list of recent legal activities going on the following drug patents of Medicure.

Activity Date Patent Number
Patent litigations
Recordation of Patent Grant Mailed 03 Aug, 2004 US6770660
Patent Issue Date Used in PTA Calculation 03 Aug, 2004 US6770660
Issue Notification Mailed 15 Jul, 2004 US6770660
Receipt into Pubs 08 Jul, 2004 US6770660
Application Is Considered Ready for Issue 06 Jul, 2004 US6770660
Dispatch to FDC 06 Jul, 2004 US6770660
Issue Fee Payment Received 15 Jun, 2004 US6770660
Issue Fee Payment Verified 15 Jun, 2004 US6770660
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 15 Jun, 2004 US6770660
Change in Power of Attorney (May Include Associate POA) 14 Jun, 2004 US6770660
Correspondence Address Change 11 Jun, 2004 US6770660
Receipt into Pubs 01 Jun, 2004 US6770660
Receipt into Pubs 08 Apr, 2004 US6770660
Workflow - File Sent to Contractor 07 Apr, 2004 US6770660
Mail Notice of Allowance 16 Mar, 2004 US6770660


Medicure's Family Patents

Medicure drugs have patent protection in a total of 6 countries. It has a significant patent presence in the US with 61.1% of its patents being US patents. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Medicure Drug List

Given below is the complete list of Medicure's drugs and the patents protecting them.


1. Aggrastat

Aggrastat is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6770660 Method for inhibiting platelet aggregation 01 May, 2023
(1 year, 5 months ago)
Expired
US6136794 Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist 29 Jan, 2019
(5 years ago)
Expired
US5978698 Angioplasty procedure using nonionic contrast media 08 Oct, 2017
(7 years ago)
Expired
US5733919 Compositions for inhibiting platelet aggregation 23 Oct, 2016
(7 years ago)
Expired
US5965581 Compositions for inhibiting platelet aggregation 23 Oct, 2016
(7 years ago)
Expired
US5972967 Compositions for inhibiting platelet aggregation 23 Oct, 2016
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aggrastat's drug page


2. Zypitamag

Zypitamag is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8829186 Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof 19 Jan, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zypitamag's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List